A 38-year-old male with treatment-resistant schizophrenia was started on clozapine 12 weeks ago after failing adequate trials of two other antipsychotics. He has been titrated to 400 mg daily. His BPRS total score has decreased from 62 to 41, representing a 34% reduction. He reports fewer auditory hallucinations and less paranoia, but continues to experience intermittent disorganized thinking. His most recent absolute neutrophil count (ANC) is 2,100 cells/microL, fasting glucose is 118 mg/dL, and he has gained 14 pounds since initiation. The PMHNP is evaluating the overall treatment response and monitoring adequacy. Which of the following best represents the appropriate evaluation of this patient's clozapine treatment course?